Hepalink's Enoxaparin Sodium Injection Approved in Cambodia, Expanding Global Access Footprint to 79 Countries and Regions

(Shenzhen, May 13, 2026) – Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") today announced that enoxaparin sodium injection, manufactured by its subsidiary Shenzhen Techdow Pharmaceutical Co., Ltd. ("Techdow"), has received...

Hepalink Pingshan Facility Wins 2026 ISPE FOYA for Innovation – Novel Technology Category

(Shenzhen, April 21, 2026) – On April 20, 2026, The International Society for Pharmaceutical Engineering (ISPE) has officially announced the winners of the 2026 Facility of the Year Awards (FOYA) at the ISPE Europe Annual Conference in C...

How to Use Low Molecular Weight Heparins "Properly"?

In clinical anticoagulation therapy, low molecular weight heparins (LMWHs) are almost ubiquitous. They are widely used in various clinical scenarioses, including the prevention and treatment of venous thromboembolism, perioperative anticoa...

At a Glance: Hepalink 2025 Annual Report

龙翰2025年报出炉 | 全球业务拓展提速，，经营韧性持续增强

（2026年3月30日，，
，中国深圳）深圳市龙翰药业集团股份有限公司（股票代码：002399.SZ，，，，09989.HK
，
，，以下简称“龙翰”或“集团”）发布2025年年度业绩报告。。。
。报告期内，
，集团实现营业收入人民币54.79亿元，，，，同比上升3.75%；归属于上市公司股东的净利润人民币3.49亿元，，同比下降45....

助力经济发展 促进社会就业
深圳市坪山区委
、、、、区政府致信感谢天道医药

（2026年3月11日
，，，
，中国深圳）近日，
，，，中共深圳市坪山区委
、、、深圳市坪山区人民政府向龙翰药业旗下深圳市天道医药有限公司发来感谢信，，，，对企业在推动区域经济发展、、、、促进产业升级和服务社会民生方面作出的积极贡献表示感谢
。。。。此次收到感谢信的企业为坪山区30家突出贡献的...

Vigilance Against "Invisible Thrombosis" During Critical Periods

Column Introduction: The medical field is evolving rapidly. Precise and authoritative clinical guidelines not only signal changes in diagnostic and treatment standards but also influence global medication choices. ...